Bulletin
Investor Alert

INmune Bio Inc.

NAS: INMB

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

May 26, 2023, 4:00 p.m.

/zigman2/quotes/206182062/composite

$

7.57

Change

+0.45 +6.32%

Volume

Volume 30,688

Quotes are delayed by 20 min

/zigman2/quotes/206182062/composite

Previous close

$ 7.12

$ 7.57

Change

+0.45 +6.32%

Day low

Day high

$7.10

$7.61

Open

52 week low

52 week high

$5.75

$10.75

Open

Company Description

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was...

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Valuation

Price to Sales Ratio

303.90

Price to Book Ratio

1.89

Enterprise Value to EBITDA

-3.83

Enterprise Value to Sales

399.06

Total Debt to Enterprise Value

0.20

Efficiency

Revenue/Employee

37,400.00

Income Per Employee

-2,729,900.00

Receivables Turnover

0.05

Total Asset Turnover

0.00

Liquidity

Current Ratio

5.92

Quick Ratio

5.92

Cash Ratio

4.78

Profitability

Operating Margin

-6,938.77

Pretax Margin

-7,299.20

Net Margin

-7,299.20

Return on Assets

-30.04

Return on Equity

-38.91

Return on Total Capital

-30.37

Return on Invested Capital

-32.95

Capital Structure

Total Debt to Total Equity

25.47

Total Debt to Total Capital

20.30

Total Debt to Total Assets

18.72

Long-Term Debt to Equity

17.01

Long-Term Debt to Total Capital

13.56

Officers and Executives

Name Age Officer Since Title
Dr. Raymond J. Tesi 64 2015 Chairman, President, Chief Executive Officer & CMO
Mr. David J. Moss 49 2015 Chief Financial Officer, Secretary & Treasurer
Ms. Tara Lehner - - Vice President-Clinical Operations
Dr. Mark Lowdell 57 2015 Chief Scientific & Manufacturing Officer
Mr. Joshua S. Schoonover - - Associate General Counsel

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/17/2023 David J. Moss
CFO, Treasurer & Secretary
2,500   Acquisition at $6.42 per share. 16,050
05/27/2022 David J. Moss
CFO, Treasurer & Secretary
3,000   Acquisition at $6.79 per share. 20,370
05/26/2022 Raymond J. Tesi
President and CEO; Director
6,300   Acquisition at $6.41 per share. 40,383
05/26/2022 David J. Moss
CFO, Treasurer & Secretary
7,700   Acquisition at $6.27 per share. 48,279
03/22/2022 Raymond J. Tesi
President and CEO; Director
23,724   Award at $8.43 per share. 199,993
03/22/2022 Mark Lowdell
Chief Scientific Officer
23,590   Award at $8.43 per share. 198,863
03/22/2022 David J. Moss
CFO, Treasurer & Secretary
17,793   Award at $8.43 per share. 149,994
03/22/2022 J. Kelly Ganjei
Director
17,793   Award at $8.43 per share. 149,994
11/17/2021 Scott Juda
Director
2,500   Acquisition at $13.55 per share. 33,875
11/03/2021 Raymond J. Tesi
President and CEO; Director
3,626   Disposition at $20 per share. 72,520
11/03/2021 Mark Lowdell
Chief Scientific Officer
701   Disposition at $20 per share. 14,020
11/03/2021 David J. Moss
CFO, Treasurer & Secretary
1,025   Disposition at $20 per share. 20,500
10/27/2021 Raymond J. Tesi
President and CEO; Director
6,517   Disposition at $20 per share. 130,340
10/27/2021 Mark Lowdell
Chief Scientific Officer
2,357   Disposition at $20 per share. 47,140
10/27/2021 David J. Moss
CFO, Treasurer & Secretary
2,079   Disposition at $20 per share. 41,580
10/25/2021 David J. Moss
CFO, Treasurer & Secretary
13   Disposition at $20 per share. 260
10/22/2021 Raymond J. Tesi
President and CEO; Director
23,616   Disposition at $20 per share. 472,320
10/22/2021 Mark Lowdell
Chief Scientific Officer
400   Disposition at $20 per share. 8,000
10/22/2021 David J. Moss
CFO, Treasurer & Secretary
1,142   Disposition at $20 per share. 22,840
09/03/2021 Xencor, Inc.
108,000   Derivative/Non-derivative trans. at $7.8 per share. 842,400
/news/latest/company/us/inmb

MarketWatch News on INMB

  1. INmune Bio downgraded to neutral from buy at B. Riley

    7:51 a.m. May 24, 2022

    - Tomi Kilgore

  2. INmune Bio stock price target cut to $7 from $14 at B. Riley

    7:52 a.m. May 24, 2022

    - Tomi Kilgore

  3. Robinhood investors are propping up this stock market, says JPMorgan

    9:33 a.m. Sept. 2, 2021

    - Barbara Kollmeyer

  4. Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks

    11:50 a.m. July 7, 2021

    - Barron's Online

  5. INmune Bio stock price target raised to $42 from $32 at Maxim Group

    8:31 a.m. July 7, 2021

    - Tomi Kilgore

  6. INmune Bio started at buy with $29 stock price target at B. Riley

    7:23 a.m. April 21, 2021

    - Tomi Kilgore

  7. INmune Bio stock price target raised to $32 from $16 at Maxim Group

    8:39 a.m. Jan. 22, 2021

    - Tomi Kilgore

  8. INmune Bios started at buy with $13 stock price target at Maxim Group

    7:38 a.m. March 19, 2019

    - Tomi Kilgore

/news/nonmarketwatch/company/us/inmb

Other News on INMB

  1. 10-Q: INMUNE BIO, INC.

    4:04 p.m. May 3, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: INMUNE BIO, INC.

    6:12 p.m. March 2, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. INmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript

    6:35 p.m. Nov. 3, 2022

    - Seeking Alpha

  4. 10-Q: INMUNE BIO, INC.

    4:02 p.m. Nov. 2, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

    5:00 a.m. Aug. 4, 2022

    - Motley Fool

  6. 10-Q: INMUNE BIO, INC.

    4:16 p.m. Aug. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

At a Glance

INmune Bio, Inc.

225 NE Mizner Boulevard

Suite 640

Boca Raton, Florida 33432

Phone

1 8589643720

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

Revenue

$374,000

Net Income

$-27.30M

2022 Sales Growth

106.6%

Employees

10.00

/news/pressrelease/company/us/inmb

Press Releases on INMB

Link to MarketWatch's Slice.